Merck Manual

Please confirm that you are a health care professional

Loading

Secondary Aldosteronism

By

Ashley B. Grossman

, MD, University of Oxford; Fellow, Green-Templeton College

Last full review/revision Sep 2020| Content last modified Sep 2020
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Topic Resources

Secondary aldosteronism is increased adrenal production of aldosterone in response to nonpituitary, extra-adrenal stimuli such as renal hypoperfusion. Symptoms are similar to those of primary aldosteronism. Diagnosis includes measurement of plasma aldosterone levels and plasma renin activity. Treatment involves correcting the cause.

Secondary aldosteronism is caused by reduced renal blood flow, which stimulates the renin-angiotensin mechanism with resultant hypersecretion of aldosterone. Causes of reduced renal blood flow include

  • Obstructive renal artery disease (eg, atheroma, stenosis)

  • Renal vasoconstriction (as occurs in accelerated hypertension)

  • Edematous disorders (eg, heart failure, cirrhosis with ascites, nephrotic syndrome)

Secretion may be normal in heart failure, but hepatic blood flow and aldosterone metabolism are reduced, so circulating levels of the hormone are high.

Symptoms and Signs

Symptoms are similar to those of primary aldosteronism and include hypokalemic alkalosis that causes episodic weakness, paresthesias, transient paralysis, and tetany. In many cases, the only manifestation is hypertension. Peripheral edema may be present depending on etiology.

Diagnosis

  • Serum electrolyte levels

  • Plasma aldosterone

  • Plasma renin activity (PRA)

Diagnosis is suspected in patients with hypertension and hypokalemia.

Initial laboratory testing consists of plasma aldosterone levels and plasma renin activity (PRA). Ideally, the patient should not take any drugs that affect the renin-angiotensin system (eg, thiazide diuretics, angiotensin-converting enzyme [ACE] inhibitors, angiotensin antagonists, beta-blockers) for 4 to 6 weeks before tests are done. Elevated aldosterone and plasma renin activity is indicative of secondary aldosteronism. The principal differences between primary and secondary aldosteronism are shown in the table Differential Diagnosis of Aldosteronism.

Table
icon

Differential Diagnosis of Aldosteronism

Clinical Finding

Primary Aldosteronism

Secondary Aldosteronism

Adenoma

Hyperplasia

Renovascular or Accelerated Hypertension

Edematous Disorders†

Blood pressure

↑↑

↑↑↑↑

N or

Edema

Rare

Rare

Rare

Present

Serum sodium

N or

N or

N or

N or

Serum potassium

N or

N or

N or

Plasma renin activity*

↓↓

↓↓

↑↑

Aldosterone

↑↑

* When corrected for age; elderly patients have lower mean plasma renin activity.

† Examples of edematous disorders are heart failure, nephrotic syndrome, and cirrhosis.

↑↑↑↑= very greatly increased; ↑↑= greatly increased; = increased; ↓↓= greatly decreased; = decreased; N = normal.

Treatment

  • Treament of cause

  • Sometimes aldosterone antagonists

Treatment involves correcting the cause. Hypertension can usually be controlled with a selective aldosterone blocker such as spironolactone, starting with 50 mg orally once a day and increasing over 1 to 3 months to a maintenance dose, usually around 100 mg once a day. Another potassium-sparing diuretic can be used instead of spironolactone. The more specific drug eplerenone 50 mg orally once a day to 200 mg orally twice a day may be used because, unlike spironolactone, it does not block the androgen receptor (which may result in gynecomastia); it is the drug of choice for long-term treatment in men if low-dose spironolactone is ineffective.

Key Points

  • Diagnosis is suspected in hypertensive patients with hypokalemia.

  • Initial testing includes measurement of plasma aldosterone and plasma renin activity.

  • Unlike in primary aldosteronism, plasma renin activity is elevated.

  • Treatment includes correcting the cause.

  • Hypertension may be controlled with aldosterone antagonists.

Drugs Mentioned In This Article

Drug Name Select Trade
ALDACTONE
INSPRA
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read

Also of Interest

Videos

View All
Overview of Acid-Base Maps and Compensatory Mechanisms
Video
Overview of Acid-Base Maps and Compensatory Mechanisms
3D Models
View All
Male Endocrine System
3D Model
Male Endocrine System

SOCIAL MEDIA

TOP